Influvac

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic, the active ingredient in Influvac, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It induces immunity to prevent influenza caused by influenza A and B viruses in at‑risk populations.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac is a seasonal influenza vaccine used to prevent infection by influenza A and B viruses.

- Seasonal influenza prevention: provides active immunity against circulating influenza A (including A/Vic) and B (including B/Austria/1359417/2021‑like) strains. - High‑risk population protection: reduces the incidence of flu in elderly, immunocompromised, or individuals with chronic medical conditions. - Public health immunisation: contributes to community‑level protection during annual influenza seasons.

Common Side Effects: - Injection site pain: mild to moderate soreness at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Headache or myalgia: mild headache or muscle aches. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - Seizures: infrequent occurrence, especially in individuals with a history of seizures. - Severe allergic reaction: hives, swelling of face or throat, difficulty breathing.

Before receiving Influvac, consider the following precautions. - Allergy assessment: avoid if there is a known severe allergy to any vaccine component. - Guillain‑Barré history: consult a healthcare professional if the individual has previously experienced Guillain‑Barré syndrome. - Pregnancy considerations: discuss vaccination with a physician to weigh benefits and risks. - Immunocompromised status: vaccine may be less effective; monitor immune response. - Age limitation: not recommended for children younger than six months. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac may interact with other medical products; monitor as indicated.

Major Interactions (Avoid): - Concurrent administration of blood products or immunoglobulins: may diminish vaccine efficacy. - Live attenuated vaccines given within 4 weeks: could interfere with immune response.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy): may reduce antibody production. - Antipyretic or analgesic use before vaccination: can mask early signs of adverse reactions. - Antiviral medications (e.g., oseltamivir) started shortly after vaccination: may affect immune response. - Seasonal influenza prophylaxis agents: coordinate timing to avoid overlapping immune stimulation.